Immunome (IMNM)

• Market cap: $2.57B
• 1 day: -0.92%
• 5 days: -2.95%
• 1 month: 1.25%
• 3 months: -13.05%
• 6 months: 33.71%
• Year to date: 9.17%
• 1 year: 156.55%
• 5 years: -9.3%
• 10 years: 69%
• Sector: Healthcare
• Industry: Biotechnology

About: Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Employees: 177